Overview
- Up to 350 R&D roles are set to go across the US and UK, with about 50 posts expected at Stevenage, subject to final confirmation in the coming months.
- GSK says R&D investment rose to £6.4 billion in 2024—nearly 90% higher than in recent years—and will increase to back priority medicines.
- Luke Miels, who became chief executive in January, is due to present his first full-year results this week.
- Reporting indicates management is weighing potential cost savings and European manufacturing footprint changes pending late-stage trial readouts.
- In January GSK agreed to buy RAPT Therapeutics to strengthen its inflammatory and immunology pipeline beyond 2031.